Radioactive iodine therapy

被引：42

作者：

Lee, Stephanie L. ^{[1
]}

机构：

[1] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA

来源：

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY | 2012年 / 19卷 / 05期

关键词：

hyperthyroidism; radioactive iodine; thyroid cancer; DIFFERENTIATED THYROID-CANCER; RECOMBINANT HUMAN THYROTROPIN; 2ND PRIMARY MALIGNANCIES; RADIOIODINE THERAPY; PRACTICE RECOMMENDATIONS; HORMONE WITHDRAWAL; REMNANT ABLATION; RADIATION SAFETY; DIETARY IODINE; GRAVES-DISEASE;

D O I：

10.1097/MED.0b013e328357fa0c

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review Review of the management decisions that must be made by the endocrinologist during the use of radioactive iodine (RAI) therapy of hyperthyroidism and differentiated thyroid cancer. Recent findings Since the 1940s radioactive I-131 (RAI) therapy has been a major component of the treatment of hyperthyroidism and differentiated thyroid cancer. RAI is the most common definitive treatment of hyperthyroidism. Pretherapy decisions including use of antithyroid medication and low-iodine diet will be discussed with the relevant supportive literature. The method of semi-quantitative calculation used for RAI treatment of hyperthyroidism will be described. Evidence-based guideline for the management of differentiated thyroid cancer by the American Thyroid Association, new drug development and recent randomized controlled trials have changed current practice of how RAI is used for remnant ablation and adjuvant therapy of differentiated thyroid cancer. Summary RAI is a common tool for the endocrinologist in the management of hyperthyroidism and differentiated thyroid cancer. Review of the management decisions and practice of RAI therapy will educate the endocrinologist of the literature supporting current RAI use in hyperthyroidism and new developments in limiting the radiation exposure to the patients with differentiated thyroid cancer.

引用

页码：420 / 428

页数：9

共 62 条

[21] Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal [J].

Elisei, R. ;

Schlumberger, M. ;

Driedger, A. ;

Reiners, C. ;

Kloos, R. T. ;

Sherman, S. I. ;

Haugen, B. ;

Corone, C. ;

Molinaro, E. ;

Grasso, L. ;

Leboulleux, S. ;

Rachinsky, I. ;

Luster, M. ;

Lassmann, M. ;

Busaidy, N. L. ;

Wahl, R. L. ;

Pacini, F. ;

Cho, S. Y. ;

Magner, J. ;

Pinchera, A. ;

Ladenson, P. W. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (11) :4171-4179

[22]

Fast S, 2012, J CLIN ENDOCRINOL ME

[23] Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Nodular Goiter Allows Major Reduction of the Radiation Burden with Retained Efficacy [J].

Fast, Soren ;

Hegedus, Laszlo ;

Grupe, Peter ;

Nielsen, Viveque Egsgaard ;

Bluhme, Christa ;

Bastholt, Lars ;

Bonnema, Steen Joop .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (08) :3719-3725

[24] Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure [J].

Gabriel, Sophie ;

Farman-Ara, Bardia ;

Bourrelly, Marc ;

Carpentier, Olivier ;

Sebag, Frederic ;

Palazzo, Fausto F. ;

De Micco, Catherine ;

Mancini, Julien ;

Henry, Jean-Francois ;

Mundler, Olivier ;

Taieb, David .

NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (09) :829-833

[25] USE OF LITHIUM AS AN ADJUNCT TO RADIOIODINE THERAPY OF THYROID-CARCINOMA [J].

GERSHENGORN, MC ;

IZUMI, M ;

ROBBINS, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1976, 42 (01) :105-111

[26] Modified-Release Recombinant Human TSH (MRrhTSH) Augments the Effect of 131I Therapy in Benign Multinodular Goiter: Results from a Multicenter International, Randomized, Placebo-Controlled Study [J].

Graf, H. ;

Fast, S. ;

Pacini, F. ;

Pinchera, A. ;

Leung, A. ;

Vaisman, M. ;

Reiners, C. ;

Wemeau, J. L. ;

Huysmans, D. ;

Harper, W. ;

Driedger, A. ;

de Souza, H. Noemberg ;

Castagna, M. G. ;

Antonangeli, L. ;

Braverman, L. ;

Corbo, R. ;

Dueren, C. ;

Proust-Lemoine, E. ;

Edelbroek, M. A. ;

Marriott, C. ;

Rachinsky, I. ;

Grupe, P. ;

Watt, T. ;

Magner, J. ;

Hegedus, L. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1368-1376

[27]

Hänscheid H, 2006, J NUCL MED, V47, P648

[28] Comments Regarding Practice Recommendations of the American Thyroid Association for Radiation Safety in the Treatment of Thyroid Disease with Radioiodine [J].

Hennessey, James V. ;

Parker, J. Anthony ;

Kennedy, Rosemary ;

Garber, Jeffrey R. .

THYROID, 2012, 22 (03) :336-337

[29] RADIOACTIVE IODINE IN THE STUDY OF THYROID PHYSIOLOGY .7. THE USE OF RADIOACTIVE IODINE THERAPY IN HYPERTHYROIDISM [J].

HERTZ, S ;

ROBERTS, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1946, 131 (02) :81-86

[30] IS CALCULATION OF THE DOSE IN RADIOIODINE THERAPY OF HYPERTHYROIDISM WORTH WHILE [J].

JARLOV, AE ;

HEGEDUS, L ;

KRISTENSEN, LO ;

NYGAARD, B ;

HANSEN, JM .

CLINICAL ENDOCRINOLOGY, 1995, 43 (03) :325-329

← 1 2 3 4 5 6 7 →